10-Q: Standard BioTools Q3 Loss Widens Amid Restructuring, Divestiture

Standard BioTools Inc. reported a widened net loss in Q3 2025, driven by restructuring charges and a decline in revenue, while progressing with the divestiture of its SomaScan Business.

Summary

• Net loss widened to $34.687 million for the three months ended September 30, 2025, compared to $26.938 million for the same period in 2024.
• Total revenue decreased by 11% to $19.552 million in Q3 2025 from $22.086 million in Q3 2024, primarily due to macroeconomic pressures on customer spending.
• Product revenue declined by 13% in Q3 2025, with consumables revenue down 17% and instruments revenue down 3%.
• Gross profit decreased by 22% to $9.484 million in Q3 2025, compared to $12.126 million in Q3 2024.
• Operating expenses increased by 9% in Q3 2025, largely driven by a 303% increase in restructuring and related charges.
• Restructuring and related charges totaled $9.428 million in Q3 2025, up from $2.341 million in Q3 2024, reflecting workforce reductions impacting approximately 20% of the global workforce and R&D consolidation.
• The divestiture of the SomaScan Business to Illumina for up to $425 million (comprising an upfront payment of $350 million in cash and up to $75 million in earnout payments) is expected to close in the first half of 2026.
• Net cash used in operating activities significantly decreased by $56.2 million to $73.153 million for the nine months ended September 30, 2025, compared to $129.395 million in the prior year period.
• The accumulated deficit reached $1,279.8 million as of September 30, 2025.

Sentiment

Score: 3

Explanation: The company reported a widened net loss and declining revenue, driven by macroeconomic pressures and substantial restructuring charges, including a 20% workforce reduction. While the divestiture of the SomaScan Business is progressing and cash used in operations improved, the immediate financial performance is weak, and the company faces ongoing litigation and an accumulated deficit.

Positives

• Net cash used in operating activities significantly decreased by $56.2 million for the nine months ended September 30, 2025, compared to the same period in 2024, indicating improved operational cash burn.
• Transaction and integration expenses decreased by 99% in Q3 2025 and 94% for the nine months, as the majority of costs related to the SomaLogic merger were one-time in nature.
• Loss from discontinued operations decreased by 40% in Q3 2025 and 48% for the nine months, due to restructuring activities within the SomaScan Business.
• The first commercial sale of co-branded kits with Illumina occurred in September 2025, triggering $0.6 million in revenue recognition.
• Existing liquidity and capital sources are expected to be sufficient to support operations for at least the next 12 months.
• Interest expense decreased by 99% for both the three and nine months ended September 30, 2025, due to the full repayment of term loan and convertible notes in 2024.

Negatives

• Net loss widened to $34.687 million in Q3 2025 from $26.938 million in Q3 2024.
• Total revenue declined by 11% in Q3 2025 and 7% for the nine months, attributed to macroeconomic pressures, budgetary limitations, and constrained funding environments.
• Gross profit decreased by 22% in Q3 2025 and 7% for the nine months, primarily due to the decline in revenue.
• Restructuring and related charges increased by 303% in Q3 2025 to $9.428 million, reflecting significant operational changes and costs, including a 20% global workforce reduction.
• Selling, general and administrative (SG&A) expense increased by 9% in Q3 2025 and 12% for the nine months, partly due to the reclassification of shared costs to continuing operations after the SomaScan divestiture.
• Interest income decreased by 55% in Q3 2025 and 54% for the nine months, due to lower account balances and interest rates.
• The accumulated deficit reached $1,279.8 million as of September 30, 2025, indicating a history of operating losses.
• Ongoing litigation, including a stockholder complaint and a suit from Shareholder Representative Services LLC (SRS) regarding milestone payments related to the Palamedrix Merger Agreement, with potential aggregate sales milestones of $17.5 million.

Risks

• Continued macroeconomic pressures on customer spending, including budgetary limitations and constrained funding environments, could impact purchase timing and deal closure rates.
• Failure to effectively develop and expand sales and marketing capabilities or improve productivity could harm the ability to expand the customer base and achieve broader market acceptance of products.
• Uncertainty regarding the outcome of legal proceedings may result in significant costs and divert management's attention and resources.
• Potential for unknown, contingent, or other liabilities arising from the SomaLogic merger could adversely affect the business.
• Exposure to National Institutes of Health funding pressures.
• Potential adverse effects from U.S. export controls and tariffs.
• Capital market risk could affect the ability to raise funds through securities offerings.
• If global inflation trends continue, appreciable increases in labor and other operating costs are expected.
• Exposure to foreign currency risk due to operations outside of the United States.
• The divestiture of the SomaScan Business is subject to customary closing conditions, including regulatory approval, and may be terminated under specified circumstances, potentially requiring Illumina to pay a $14.5 million reverse termination fee.

Future Outlook

The company expects the divestiture of the SomaScan Business to Illumina to close in the first half of 2026. It plans to continue significant investments in R&D, expecting R&D expenses to increase in absolute dollars. Ongoing restructuring expenses are anticipated until the South San Francisco lease terminates, and additional transaction and integration expenses are expected for future transactions. Management believes existing liquidity and capital sources will be sufficient for at least the next 12 months. The company aims to expand its protein reagents for commercial availability, focusing on mass cytometry antibody panels and detection capabilities, and to grow its single-cell proteomics database and AI/ML analytics. Total revenue is expected to vary based on new contracts, customer consumption, salesforce productivity, significant transactions, and seasonality. If global inflation trends persist, appreciable increases in labor and other operating costs are expected.

Management Comments

• "We are committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team."
• "Our established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster."
• "We have built a solid foundation supporting a differentiated portfolio of life science tools, offering broad multi-omic capabilities that drive innovation and accelerate the pace of drug development."
• "Our solutions are designed to unlock complex biological information across plasma, single-cell and spatial proteomics, as well as genomic analyses, enabling researchers to explore disease mechanisms with unprecedented depth and precision."
• "By integrating our advanced platforms – CyTOF, Hyperion, and Biomark – we empower scientists to generate high-content data across therapeutic areas, from immuno-oncology to neurology and infectious diseases."
• "The revenue decline was anticipated by management and reflects continued macroeconomic pressures on customer spending, including budgetary limitations and constrained funding environments that have impacted purchase timing and deal closure rates."
• "We continue to focus on improving operating discipline through the implementation of restructuring plans and lean Standard BioTools Business System principles to build more efficient operations and reduce costs."
• "We intend to reduce manufacturing costs, in part, by modifying our manufacturing processes to use materials and technologies that provide equal or greater quality at lower cost, improving how we manage our materials and negotiating favorable terms for our materials purchases."

Industry Context

The company operates in the competitive life science tools industry, specializing in multi-omics (proteomics and genomics) for translational and clinical research. The divestiture of the SomaScan Business to Illumina represents a strategic shift, allowing the company to focus on its mass cytometry and microfluidics businesses, potentially indicating a move towards specialization. The collaboration with Illumina for co-branded kits aligns with broader industry trends of strategic partnerships to leverage complementary technologies. The reported revenue decline due to macroeconomic pressures and constrained funding environments reflects challenges common to the life science tools sector, which is often sensitive to research funding cycles. The company's emphasis on expanding its single-cell proteomics database and AI/ML analytics is consistent with the industry's increasing focus on data-driven discovery and advanced analytical capabilities.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks for a direct assessment.
• The decline in revenue attributed to 'macroeconomic pressures on customer spending, including budgetary limitations and constrained funding environments' suggests the company is experiencing challenges common to the broader life science tools sector, which can be sensitive to research funding cycles and economic conditions.
• The company's stated commitment to 'setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team' represents internal aspirations rather than external comparative performance.

Management Changes

Corporate Governance

Legal Proceedings

• Stockholder litigation filed in December 2023 regarding the SomaLogic Merger, alleging a materially deficient registration statement and breach of fiduciary duty. A motion to dismiss was denied on August 7, 2025, and the company filed its answer and affirmative defenses on October 10, 2025.
• Litigation with Shareholder Representative Services LLC (SRS) filed July 3, 2025, against SomaLogic, alleging breaches of the Palamedrix Merger Agreement related to milestone payments totaling an aggregate of $17.5 million. SomaLogic moved to compel arbitration and/or dismiss the action on August 4, 2025.
• A demand was received on June 4, 2024, from a stockholder to inspect books and records relating to the prior conversion of Series B Preferred Stock.
• Settled previously outstanding litigation with a former SomaLogic stockholder in February 2024, involving the relinquishment of 422,048 common shares.
• Settled previously outstanding litigation with former SomaLogic stockholders in May 2024 for $6.2 million, consisting of a repurchase of approximately 1.84 million shares and a cash payment of $1.8 million.

Related Party Transactions

• Eli Casdin, a director and principal stockholder, and his affiliates received 26,515,248 shares of common stock (including shares issuable upon vesting of RSUs and exercise of options and warrants) in connection with the SomaLogic Merger and conversion of Series B Preferred Stock.
• CMLS Holdings II LLC (CMLS LLC), which may be indirectly beneficially owned by Mr. Casdin, received 4,824,802 shares upon warrant exercise and 7,548,000 shares of common stock in exchange for SomaLogic common stock.

Stakeholder Impact

• Shareholders: Widened net loss, declining revenue, and significant restructuring charges could negatively impact share price. The strategic divestiture and improved operational cash flow offer potential long-term benefits, but immediate financial performance and ongoing litigation create uncertainty.
• Employees: Approximately 20% of the total global workforce was impacted by reductions-in-force. The consolidation of R&D to Singapore and headquarters transfer to Boston will affect U.S. employees.
• Customers: Macroeconomic pressures and funding constraints are impacting customer spending, leading to lower sales. Improved instrument reliability may reduce service requirements.
• Suppliers: The company's intent to reduce manufacturing costs by modifying processes and negotiating favorable terms could impact suppliers.
• Creditors: The repayment of term loan and convertible notes in 2024 has reduced debt obligations, which is positive for creditors.

Next Steps

• Complete the consolidation of South San Francisco-based R&D capabilities into the Singapore facility by December 31, 2025.
• Vacate the South San Francisco office and transfer headquarters to Boston, Massachusetts by December 31, 2025.
• Close the divestiture of the SomaScan Business to Illumina in the first half of 2026.
• Continue to invest significantly in R&D to enhance existing products and services and bring new ones to market.
• Focus on improving operating discipline through restructuring plans and lean Standard BioTools Business System principles.
• Reduce manufacturing costs by modifying processes and negotiating favorable terms for materials.
• Increase the number of protein reagents for commercial availability, focusing on mass cytometry antibody panels and detection capabilities.
• Expand the single-cell proteomics database and AI/ML analytics.
• Briefing on SomaLogic's motion to compel arbitration and/or dismiss the SRS Chancery Action is not yet complete.

Key Dates

Recommendation

While the company is undergoing significant restructuring and divesting a major business unit (SomaScan) to focus on its core mass cytometry and microfluidics, the immediate financial results show a widened net loss and declining revenue due to macroeconomic pressures. The reduction in cash burn from operations and the expected cash inflow from the Illumina transaction are positive for liquidity. However, the substantial restructuring charges, ongoing litigation, and the need to demonstrate future growth in the remaining core businesses create considerable uncertainty. A 'Hold' recommendation is appropriate as investors await clearer signs of stabilization and growth from the streamlined operations, and the successful completion of the divestiture.

Keywords

Life science tools, Proteomics, Genomics, Multi-omics, Mass cytometry, Microfluidics, SomaScan, Illumina, Divestiture, Restructuring, R&D, Financial results, Q3 2025, SEC filing, 10-Q, Standard BioTools, LAB, Biotechnology, Diagnostics, Research